share_log

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Benzinga Real-time News ·  Sep 28, 2022 16:10  · Markets
  • One of the most-watched Alzheimer's therapies in the clinic,$Biogen (BIIB.US)$Inc-Eisai Limited's(OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's.

  • In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023.

  • Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's space.

$Eli Lilly and Co (LLY.US)$- Market cap: $317 billion.

  • Positive readthrough is expected from its...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment